KẾT QUẢ ĐIỀU TRỊ UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN III BẰNG HÓA XẠ ĐỒNG THỜI VỚI PHÁC ĐỒ PACLITAXEL – CARBOPLATIN

Abstract

Aims: Evaluation of some clinical and paraclinical characteristics and treatment response of Paclitaxel - Carboplatin regimen combined with concurrent radiotherapy in patients with stage III non-surgical non-small cell lung cancer (NSCLC). Patients and method of study: Retrospective and prospective study on 79 non-small cell lung cancer patients in stage III treated by Paclitaxel and Carboplatin combined with radiation therapy from December 2021 to December 2023. Results: The mean age of the study group was 63.4 ± 7.9 years, with a male-to-female ratio of 6.1:1. The age group of 60-69 years had the highest proportion of participants with 46.7%.  Stage IIIA accounted for 14.1%, stage IIIB accounted for 56.5%, and stage IIIC accounted for 29.3%. of the patients. Chest pain was the most common reason for patients to seek medical attention, accounting for 47.8% of the cases. In the study, 1 patient (1.1%) achieved a complete response, 74 patients (80.4%) achieved a partial response, 9 patients (9.8%) remained stable, and 8 patients (8.7%) progressed. After one month of treatment, the disease control rate was 91.3%. Common side effects included radiation dermatitis, which occurred in most patients with 73.9%, neutropenia in 18.5% of patients, anemia in 52.2% of patients, pneumonitis in 19.6% of patients, and esophagitis in 34.7% of patients. Conclusion: Our finding shows that concurrent chemoradiotherapy with Paclitaxel Carboplatin regimen was safe and effective in grade III non-small cell lung cancer.